Page 40 - Read Online
P. 40

Bros-Facer et al. Rare Dis Orphan Drugs J 2023;2:21  https://dx.doi.org/10.20517/rdodj.2023.26  Page 13 of 14

               DECLARATIONS
               Acknowledgments
               The authors would like to thank all respondents to the survey and their colleagues involved in the initiatives,
               including Angel Carracedo, Maria Luce Couce Pico and Maria Eugenia Vazquez-Mosquera; Giorgio Casari;
               Laurence Faivre; Alessandra Ferlini and Nicolas Garnier; Mattia Gentile; Maria Iascone; Belen Perez and
               Francesc Palau; Amanda Pichini; Birgit Raddatz and Francjan van Spronsen; Wendy Rodenburg and Els
               Voorhoeve; Christian Schaaf, Maja Hempel and Heiko Brennenstuhl; Laurent Servais; Petros Tsipouras and
               Mirjam van der Burg. We would also like to thank Maria Martinez-Fresno for her help drafting the
               questionnaire, Raye Alford for reviewing and revising the manuscript for grammar and syntax, and Kirsten
               Curnow for her help with the figures.


               Authors’ contributions
               Involved in the planning and developing of the main conceptual ideas: Bros-Facer V, Patch C
               Developed the survey with input from Maria Martinez-Fresno: Bros-Facer V, Taylor S
               Analyzed the results of the survey: Bros-Facer V
               Contributed to the writing of the manuscript: Bros-Facer V, Taylor S, Patch C


               Availability of data and materials
               Individual responses to the survey are confidential data that will be destroyed upon acceptance of the
               manuscript for publication.

               Financial support and sponsorship
               Not applicable.

               Conflicts of interest
               Bros-Facer V and Taylor S are employees of Illumina, Inc. Patch C has no conflicts of interest to declare.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright:
               © The Author(s) 2023.


               REFERENCES
               1.       Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in
                   newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945-55.
                   DOI  PubMed
               2.       Chace DH, Spitzer AR. Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench
                   to bedside. Curr Pharm Biotechnol 2011;12:965-75.  DOI  PubMed
               3.       Watson MS, Lloyd-Puryear MA, Howell RR. The progress and future of US newborn screening. Int J Neonatal Screen 2022;8:41.
                   DOI  PubMed  PMC
               4.       van Karnebeek CD, Tiebout SA, Niermeijer J, et al. Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol
                   2016;59:6-12.  DOI
               5.       McCombie  WR,  McPherson  JD,  Mardis  ER.  Next-generation  sequencing  technologies.  Cold  Spring  Harb  Perspect  Med
                   2019;9:a036798.  DOI  PubMed  PMC
               6.       Dimmock D, Caylor S, Waldman B, et al. Project baby bear: rapid precision care incorporating rWGS in 5 California children's
                   hospitals demonstrates improved clinical outcomes and reduced costs of care. Am J Hum Genet 2021;108:1231-8.  DOI  PubMed
                   PMC
   35   36   37   38   39   40   41   42   43   44   45